TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: 0.100nMAssay Description:Inhibition of His6-CHK1 expressed in baculovirus infected Sf9 cellsMore data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of human Myc-DDK-tagged IDH1 R132H mutant expressed in human U87MG cells assessed as reduction in 2-HG levels after 24 hrs by RapidFire hi...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Homo sapiens (Human))
Forma Therapeutics
US Patent
Forma Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: 2nMAssay Description:Inhibition of IDH1 R132H mutant in human HCT116 cells assessed as reduction in 2-HG levels after 24 hrs by RapidFire high-throughput mass spectrometr...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: <2nMAssay Description:Inhibition of IDH1 R132H mutant in human HCT116 cells assessed as reduction in 2-HG levels after 24 hrs by RapidFire high-throughput mass spectrometr...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: <2nMAssay Description:Inhibition of IDH1 R132C mutant in human HCT116 cells assessed as reduction in 2-HG levels after 24 hrs by RapidFire high-throughput mass spectrometr...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: <2nMAssay Description:Inhibition of IDH1 R132H mutant in human HCT116 cells assessed as reduction in 2-HG levels after 24 hrs by RapidFire high-throughput mass spectrometr...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: 3nMAssay Description:Inhibition of human Myc-DDK-tagged IDH1 R132G mutant expressed in human U87MG cells assessed as reduction in 2-HG levels after 24 hrs by RapidFire hi...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Homo sapiens (Human))
Forma Therapeutics
US Patent
Forma Therapeutics
US Patent
Affinity DataIC50: 3.80nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: 4nMAssay Description:Inhibition of human Myc-DDK-tagged IDH1 R132C mutant expressed in human U87MG cells assessed as reduction in 2-HG levels after 24 hrs by RapidFire hi...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: 4nMAssay Description:Inhibition of His6-CHK1 expressed in baculovirus infected Sf9 cellsMore data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: 4nMAssay Description:Inhibition of IDH1 R132H mutant in human HCT116 cells assessed as reduction in 2-HG levels after 24 hrs by RapidFire high-throughput mass spectrometr...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: 4nMAssay Description:Inhibition of IDH1 R132H mutant in human HCT116 cells assessed as reduction in 2-HG levels after 24 hrs by RapidFire high-throughput mass spectrometr...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: 4nMAssay Description:Inhibition of human Myc-DDK-tagged IDH1 R132H mutant assessed as reduction in NADPH consumption pre-incubated for 15 mins followed by alpha-ketogluta...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: 4nMAssay Description:Inhibition of recombinant human Myc-DDK-tagged IDH1 R132C mutant using alpha-ketoglutarate as substrate preincubated for 15 mins followed by substrat...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Homo sapiens (Human))
Forma Therapeutics
US Patent
Forma Therapeutics
US Patent
Affinity DataIC50: 4.80nMAssay Description:The cellular potency of Compound 1 in suppressing intracellular 2-HG levels was determined in cell lines expressing five different mutated IDH-1 prot...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Homo sapiens (Human))
Forma Therapeutics
US Patent
Forma Therapeutics
US Patent
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Homo sapiens (Human))
Forma Therapeutics
US Patent
Forma Therapeutics
US Patent
Affinity DataIC50: 4.80nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: 5nMAssay Description:Inhibition of human Myc-DDK-tagged IDH1 R132L mutant expressed in human U87MG cells assessed as reduction in 2-HG levels after 24 hrs by RapidFire hi...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: 5nMAssay Description:Inhibition of human recombinant CHK1 expressed in insect cells using biotinylaminohexanoyl-KKVSRSGLYRSPMPENLNRPR as substrate after 2 hrs by scintill...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Homo sapiens (Human))
Forma Therapeutics
US Patent
Forma Therapeutics
US Patent
Affinity DataIC50: 5.10nMAssay Description:Compound 1 was not initially reported as having the greatest biochemical potency compared to reports for certain other small molecule inhibitors of m...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: 6nMAssay Description:Inhibition of IDH1 R132C mutant in human HCT116 cells assessed as reduction in 2-HG levels after 24 hrs by RapidFire high-throughput mass spectrometr...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: 6nMAssay Description:Inhibition of human Myc-DDK-tagged IDH1 R132H mutant assessed as reduction in NADPH consumption pre-incubated for 15 mins followed by alpha-ketogluta...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: 6nMAssay Description:Inhibition of human Myc-DDK-tagged IDH1 R132G mutant expressed in human U87MG cells assessed as reduction in 2-HG levels after 24 hrs by rapidfire hi...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: 6nMAssay Description:Inhibition of His6-CHK1 expressed in baculovirus infected Sf9 cellsMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: 6nMAssay Description:Inhibition of human recombinant CHK1 expressed in insect cells using biotinylaminohexanoyl-KKVSRSGLYRSPMPENLNRPR as substrate after 2 hrs by scintill...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: 6nMAssay Description:Inhibition of human recombinant CHK1 expressed in insect cells using biotinylaminohexanoyl-KKVSRSGLYRSPMPENLNRPR as substrate after 2 hrs by scintill...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: 6nMAssay Description:Inhibition of human recombinant CHK1 expressed in insect cells using biotinylaminohexanoyl-KKVSRSGLYRSPMPENLNRPR as substrate after 2 hrs by scintill...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: 7nMAssay Description:Inhibition of IDH1 R132H mutant in human HCT116 cells assessed as reduction in 2-HG levels after 24 hrs by RapidFire high-throughput mass spectrometr...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: 7nMAssay Description:Inhibition of His6-CHK1 expressed in baculovirus infected Sf9 cellsMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: 7nMAssay Description:Inhibition of human recombinant CHK1 expressed in insect cells using biotinylaminohexanoyl-KKVSRSGLYRSPMPENLNRPR as substrate after 2 hrs by scintill...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
TargetSerine/threonine-protein kinase Chk1(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: 7nMAssay Description:Inhibition of human recombinant CHK1 expressed in insect cells using biotinylaminohexanoyl-KKVSRSGLYRSPMPENLNRPR as substrate after 2 hrs by scintill...More data for this Ligand-Target Pair